Owens & Minor (OMI) Projected to Post Earnings on Friday

Owens & Minor (NYSE:OMI - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Friday, May 2nd. Analysts expect Owens & Minor to post earnings of $0.20 per share and revenue of $2.66 billion for the quarter. Owens & Minor has set its FY25 guidance at $1.60-1.85 EPS and its FY 2025 guidance at 1.600-1.850 EPS.

Owens & Minor (NYSE:OMI - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported $0.55 EPS for the quarter, topping the consensus estimate of $0.53 by $0.02. The company had revenue of $2.70 billion during the quarter, compared to analysts' expectations of $2.68 billion. Owens & Minor had a negative net margin of 0.46% and a positive return on equity of 14.60%. Owens & Minor's revenue was up 1.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.69 EPS. On average, analysts expect Owens & Minor to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Owens & Minor Trading Down 0.9 %

Shares of OMI stock traded down $0.06 during trading hours on Friday, reaching $6.91. The company had a trading volume of 980,968 shares, compared to its average volume of 1,114,737. Owens & Minor has a 1-year low of $6.07 and a 1-year high of $25.60. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.09 and a quick ratio of 0.45. The firm has a market cap of $533.83 million, a price-to-earnings ratio of -10.63, a P/E/G ratio of 0.20 and a beta of 1.02. The company has a 50 day moving average of $8.18 and a 200 day moving average of $11.24.

Owens & Minor declared that its board has authorized a stock buyback program on Friday, February 28th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 13.6% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's management believes its stock is undervalued.

Insiders Place Their Bets

In related news, major shareholder Coliseum Capital Management, L acquired 354,901 shares of the business's stock in a transaction on Monday, March 3rd. The stock was purchased at an average cost of $9.19 per share, for a total transaction of $3,261,540.19. Following the completion of the transaction, the insider now directly owns 9,824,599 shares of the company's stock, valued at approximately $90,288,064.81. The trade was a 3.75 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have bought 2,718,412 shares of company stock valued at $24,495,308. 3.69% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

OMI has been the topic of a number of research analyst reports. UBS Group dropped their price target on Owens & Minor from $25.00 to $13.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Robert W. Baird raised their target price on shares of Owens & Minor from $10.00 to $11.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. JPMorgan Chase & Co. reduced their price target on shares of Owens & Minor from $14.00 to $10.00 and set an "underweight" rating for the company in a report on Monday, March 10th. Finally, Citigroup dropped their price objective on shares of Owens & Minor from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $12.50.

Owens & Minor Company Profile

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.